Please login to the form below

Not currently logged in
Email:
Password:

Dendreon CEO to step down

John Johnson to leave next summer as Provenge sales stall

Dendreon has announced that CEO John Johnson will leave the company in August next year.

The decision comes as Dendreon continues to struggle as its only product Provenge – a 'vaccine' for prostate cancer ' – fails to live up to high expectations.

According to the company's financial report, sales of Provenge declined from $325m in 2012 to $286m in 2013. This led to Dendreon dropping out the top 25 companies working in oncology.

These poor sales meant the company reported operating losses of around $300m and major job cuts.

On leaving, Johnston said: "I first joined Dendreon because of my admiration for the company as a pioneer in immunotherapy and because of my belief in the power of Provenge as a personalised cancer treatment. That belief still holds true today.”

11th June 2014

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics